Short Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Rises By 26.1%

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) saw a large growth in short interest in August. As of August 31st, there was short interest totalling 161,600 shares, a growth of 26.1% from the August 15th total of 128,200 shares. Based on an average daily volume of 76,500 shares, the short-interest ratio is currently 2.1 days. Currently, 1.0% of the shares of the company are sold short.

Telomir Pharmaceuticals Price Performance

Shares of NASDAQ:TELO traded up $0.13 during trading on Friday, hitting $6.07. 63,795 shares of the stock traded hands, compared to its average volume of 155,933. The company has a fifty day moving average price of $4.57 and a two-hundred day moving average price of $5.70. Telomir Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $20.72.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its earnings results on Tuesday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Institutional Trading of Telomir Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $241,000. Suncoast Equity Management purchased a new stake in shares of Telomir Pharmaceuticals during the 1st quarter worth $126,000. Finally, Beaird Harris Wealth Management LLC boosted its position in shares of Telomir Pharmaceuticals by 212.9% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after purchasing an additional 9,950 shares in the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.